Tesamorelin for Visceral Fat Reduction

Candidate profile

Adults with excess visceral adipose tissue (VAT) — the metabolically active abdominal fat compartment associated with cardiovascular disease, insulin resistance, and hepatic steatosis. FDA-approved for HIV-associated lipodystrophy (Egrifta), with growing off-label interest in the broader metabolic health population.

Tesamorelin targets the visceral compartment specifically. Individuals seeking general weight loss will be disappointed — total body weight change is modest. This is a precision tool for visceral fat, not a weight-loss drug.

Approach

Daily subcutaneous injection of tesamorelin, a synthetic GHRH analog that stimulates pulsatile endogenous GH release from the anterior pituitary. Unlike exogenous GH, tesamorelin preserves the hypothalamic-pituitary feedback loop — the pituitary still regulates output. The resulting GH pulses preferentially mobilize visceral fat through hepatic IGF-1-mediated lipolysis in the omental and mesenteric depots.

Protocol design

Medication: Tesamorelin, 2 mg daily

Route: Subcutaneous injection, abdominal region (rotate injection sites)

Timing: Evening or bedtime — aligns with endogenous nocturnal GH pulsatility, though clinical trials did not mandate specific timing

Duration: 26 weeks minimum (the RCT duration that demonstrated efficacy). Many practitioners extend to 52 weeks for sustained effect.

Frequency: Daily, 7 days per week

Dosing context: The 2 mg dose is the FDA-approved dose. Unlike GLP-1 agonists, tesamorelin does not require dose escalation — the full dose is administered from day one.

Important distinctions from exogenous GH:

• Preserves pulsatile secretion pattern (exogenous GH creates flat, non-physiological levels)
• Lower risk of insulin resistance (though still monitor)
• Does not suppress endogenous GH production
• Less fluid retention and joint symptoms than equivalent GH dosing

Timeline & milestones

Weeks 1–4: IGF-1 levels rise, confirming pituitary response. No visible body composition changes. Some patients report improved sleep quality (consistent with restored GH pulsatility).

Weeks 4–12: Early visceral fat mobilization begins. CT or DEXA-measured VAT starts declining. Waist circumference changes may be subtle — visceral fat loss is internal and not always reflected in external measurements.

Weeks 12–26: Measurable VAT reduction. The pivotal trials showed approximately 15% reduction in trunk fat (CT-measured) at 26 weeks versus placebo. Concurrent improvements in triglycerides and markers of hepatic steatosis are commonly observed.

Post-26 weeks: Fat regain occurs if treatment is discontinued — similar to the GLP-1 agonist story. Continuation or cycling decisions should be individualized.

Monitoring

• IGF-1 levels: Baseline, week 4, then every 3 months — confirms pituitary response and screens for excessive elevation (target: upper half of age-adjusted reference range, not supraphysiological)
• Fasting glucose and HbA1c: Baseline and every 3 months — GH-mediated insulin resistance is possible, especially in prediabetic individuals
• Body composition: CT scan (gold standard for VAT) or DEXA at baseline and week 26. Waist circumference is a secondary measure.
• Lipid panel: Baseline and week 26 — triglyceride reduction is a common secondary benefit
• Liver enzymes and hepatic fat fraction (MRI-PDFF if available): Tesamorelin has shown reduction in liver fat in NAFLD-related studies

When to adjust

• IGF-1 supraphysiological at week 4: Reduce dose to 1 mg daily and recheck in 4 weeks. Sustained IGF-1 elevation above the reference range is not acceptable.
• Fasting glucose rise >10 mg/dL from baseline: Add glucose monitoring. If progression toward diabetic range, reassess risk-benefit.
• No measurable VAT reduction at week 26 (CT-confirmed): Confirm compliance and assess for pituitary insufficiency (low IGF-1 response suggests the pituitary cannot respond to GHRH stimulation). Discontinue if non-responsive.
• Injection site reactions: Common (redness, itching in ~10% of patients). Rotate sites. Persistent or severe reactions warrant formulation review.
• Fluid retention or joint pain: Indicates GH effect is too pronounced. Reduce dose or reassess.

Evidence reality check

Tesamorelin is the only GHRH analog with FDA approval and multiple phase 3 RCTs demonstrating visceral fat reduction. The evidence base is real and replicated. However, the approved indication is narrow (HIV lipodystrophy), off-label use for general metabolic health is practitioner-driven, and the cost is substantial (~$500–800/month). Tesamorelin does not produce dramatic weight loss — it produces targeted visceral fat reduction, which is a different and arguably more metabolically important outcome.